Apollomics, Inc. Share Price & Technical Analysis
APLM · $13.92 (-1.63%)
Healthcare / Biotechnology
$13.92
-1.63%
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung …
Price chart
Seasonality
Jun has 3 positive and 2 negative years (last 5 years shown)
-2% return in Jun, 3% avg return in past 3 year Jun month.
-30% return in 2026, 21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 12% | -20% | -14% | 6% | -2% | – | – | – | – | – | – | -30% |
| 25 | -15% | -28% | -3% | 2% | 2% | 6% | -9% | -33% | 372% | -24% | 0% | 24% | 293% |
| 24 | -17% | -9% | 0% | -38% | -31% | -30% | -10% | -38% | 18% | -16% | -25% | 7% | -189% |
| 23 | 1% | 1% | 130% | -78% | -35% | 34% | -9% | -6% | -21% | -78% | 16% | 5% | -41% |
| 22 | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% | 0% | 1% | 1% | 1% | 5% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$31.07M
P/E ratio
—
52W high
$42.12
52W low
$3.66
Volume
8,459
Beta
1.52
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Apollomics, Inc. share price today?
- Apollomics, Inc. (APLM) last traded around $13.92 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does APLM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for APLM. Download the app for real-time alerts.
- How can I analyze Apollomics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.